N/A N=62 Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline
Middle-aged Adults · Major Depressive Disorder
Primary: Nitric Oxide (NO)-Mediated Endothelium-dependent Dilation (EDD) — 70; 74 percentage — p=>0.05
N/A N=16 Using Electrical Nerve Stimulation to Control Atrial Fibrillation
Atrial Fibrillation
Primary: Change in AF Burden — -0.4; -2.4 percentage of time in AF
N/A N=11,197 Clinical Decision Support for Opioid Use Disorders in Medical Settings (COMPUTE 2.0)
Opioid-use Disorder
Primary: Number of Patients With OUD Diagnosis — 36; 24 participants — p=<0.05
Phase 3 N=198 Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of COPD Exacerbations. — 2.0; 3.0 number of exacerbations — p=<0.01
N/A N=228 Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537
N/A N=80 Mechanisms of Affective Touch in Chronic Pain
Fibromyalgia
Primary: Chronic Pain Intensity Using the Chronic Pain Grade Questionnaire — 66.0; 16.8 score on a scale
Phase 3 N=449 A Trial to Assess the Antipsychotic Efficacy of ITI-007
Schizophrenia
Primary: Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score — -12.9; -14.5; -10.3 units on a scale — p=0.182
N/A N=309 Decreasing Stress in Diabetes
Stress · Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1
Primary: Change in A1CNow® Self-Check Hemoglobin A1c (HbA1c) Home Kit Values From Baseline to 6-Months (6MO) — 8.50; 8.60; 8.15; 8.24 percentage of glycated hemoglobin — p=0.96
Phase 3 N=161 Self-management of Sedative Therapy by Ventilated Patients
Critical Illness · Anxiety · Respiratory Failure
Primary: Anxiety Rating Using the 100mm Vertical Visual Analog Scale — 44.4; 43.4; 40.5; 33.1 score on a scale — p=0.30
Phase 2 N=2 Intralesional HPV Vaccine for Condylomata
Human Papilloma Virus · Warts · Warts, Genital
Primary: Change in Wart Number — 0.5 warts
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
Phase 3 N=696 A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score — -15.0; -14.6; -15.1; -20.5 units on a scale — p=0.972
N/A N=63 Intra-procedural Transthoracic EChocardiogram to Facilitate Left Bundle Branch Area Pacing (LBBAP)
Heart Failure
Primary: A Positive Success Rate of LBBAP Utilization With Intraprocedural Transthoracic Echocardiogram — 19; 10 Participants
Phase 1 N=24 Weekly BI 836880 in Patients With Advanced Solid Tumors
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)